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Long-range epigenetic regulation is conferred
by genetic variation located at thousands of
independent loci
Mathieu Lemire1, Syed H.E. Zaidi1, Maria Ban2, Bing Ge3, Dylan Aı¨ssi4,5,6, Marine Germain4,5,6, Irfahan Kassam7,
Mike Wang1, Brent W. Zanke8, France Gagnon7, Pierre-Emmanuel Morange9,10,11, David-Alexandre Tre´goue¨t4,5,6,
Philip S. Wells8, Stephen Sawcer2, Steven Gallinger12,13, Tomi Pastinen3 & Thomas J. Hudson1,14,15
The interplay between genetic and epigenetic variation is only partially understood. One form
of epigenetic variation is methylation at CpG sites, which can be measured as methylation
quantitative trait loci (meQTL). Here we report that in a panel of lymphocytes from 1,748
individuals, methylation levels at 1,919 CpG sites are correlated with at least one distal (trans)
single-nucleotide polymorphism (SNP) (Po3.2 10 13; FDRo5%). These trans-meQTLs
include 1,657 SNP–CpG pairs from different chromosomes and 262 pairs from the same
chromosome that are41Mb apart. Over 90% of these pairs are replicated (FDRo5%) in at
least one of two independent data sets. Genomic loci harbouring trans-meQTLs are
signiﬁcantly enriched (Po0.001) for long non-coding transcripts (2.2-fold), known epigenetic
regulators (2.3-fold), piwi-interacting RNA clusters (3.6-fold) and curated transcription
factors (4.1-fold), including zinc-ﬁnger proteins (8.75-fold). Long-range epigenetic networks
uncovered by this approach may be relevant to normal and disease states.
DOI: 10.1038/ncomms7326 OPEN
1 Ontario Institute for Cancer Research, Toronto, Ontario, Canada M5G 0A3. 2Department of Clinical Neurosciences, University of Cambridge, Cambridge
Biomedical Campus, Hills Road, Cambridge CB2 0QQ, UK. 3McGill University and Genome Que´bec Innovation Centre, Montre´al, Que´bec, Canada H3A 0G1.
4 INSERM, UMR-S 1166, Paris F-75013, France. 5 Sorbonne Universite´s, UPMC Univ Paris 06, UMR_S 1166, Team Genomics and Pathophysiology of
Cardiovascular Diseases, Paris F-75013, France. 6 ICAN Institute for Cardiometabolism and Nutrition, Paris F-75013, France. 7 Dalla Lana School of Public
Health, University of Toronto, College Street, Toronto, Ontario, Canada M5T 3M7. 8Department of Medicine, University of Ottawa, Ottawa Hospital Research
Institute, Ottawa, Ontario, Canada K1H 8L6. 9 Laboratory of Haematology, La Timone Hospital, Marseille F-13385, France. 10 INSERM, UMR_S 1062, Nutrition
Obesity and Risk of Thrombosis, Marseille F-13385, France. 11 Aix-Marseille University, UMR_S 1062, Nutrition Obesity and Risk of Thrombosis, Marseille
F-13385, France. 12 Samuel Lunenfeld Research Institute, Toronto, Ontario, Canada M5S 1X5. 13 Division of General Surgery, Toronto General Hospital, Toronto,
Ontario, Canada M5G 2C4. 14Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada M5S 1A1. 15 Department of Molecular
Genetics, University of Toronto, Toronto, Ontario, Canada M5S 1A1. Correspondence and requests for materials should be addressed to M.L.
(email: mathieu.lemire@oicr.on.ca).
NATURE COMMUNICATIONS | 6:6326 |DOI: 10.1038/ncomms7326 | www.nature.com/naturecommunications 1
& 2015 Macmillan Publishers Limited. All rights reserved.
C
haracterizing the relationships between genetic variants
and functional elements of the genome is needed to
advance our understanding of phenotypic diversity and
characterize how genetic variation can perturb cell function and
affect disease predisposition. Although cells contain a myriad of
biomolecules that can potentially be assayed across large numbers
of genetically characterized samples, analyses of nucleic elements
such as transcript expression and CpG methylation are ideally
suited for genome-wide comparisons with currently available
technologies. In general, the detection of association between
nearby (cis) genetic variants and functional elements has been
easier to detect and validate than distal (trans) relationships,
because of the multiple testing burden that arises when trans-
associations are explored.
Expression quantitative trait loci (eQTL) studies in the past
decade have demonstrated that gene transcript levels in a cell are
frequently associated with nearby genetic variants (cis-eQTLs),
which in turn are enriched for single-nucleotide polymorphisms
(SNPs) associated with disease1,2. In parallel, mechanistic links
between the disease-associated variants and the biology of the
disease governed by local gene expression alterations are
emerging3. The detection of eQTLs spanning long distances
(trans-eQTLs) has been challenging, particularly due to the
multiple testing burden that occurs when genome-wide sets of
variants are compared with genome-wide sets of genes. To
address this limitation, Westra et al.4 performed an eQTL meta-
analysis in 5,311 peripheral blood samples. They furthermore
reduced the number of variants to test for trans-eQTLs to 4,542
SNPs that have been implicated in complex traits by genome-
wide association studies. This allowed the detection and
replication of trans-eQTLs for 233 disease-associated SNPs (at
103 independent loci), and provided insight into the pathogenesis
of disease for selected variants identiﬁed in their screen.
An alternate approach to mapping regulatory relationships
between genetic variants and distal genes is by correlating genetic
variants with genome-wide epigenomic proﬁles. Notwithstanding
rapid developments in epigenome-mapping methods that can
explore a large number of chromatin modiﬁcations, the only
approach that can screen thousands of samples needed to detect
trans-acting relationships in a genome-wide fashion is an array-
based multiplex assay that interrogates a multitude of methylation
sites in parallel. A ﬁrst-generation array that measured methyla-
tion levels at 22,290 CpG dinucleotides in 77 lymphoblastoid cell
lines was used to detect associations between genome-wide SNPs
and CpG methylation5. After applying a genome-wide false
discovery rate (FDR) of 10% (P¼ 2.1 10 10), they detected 27
putative cis-association signals, most of which involved SNPs and
CpG sites located within 50 kb of each other and 10 trans-
association signals. Despite the limitations in the sample size used
in this study, these preliminary studies demonstrated the
potential to map trans-regulatory relationships between genetic
variants and distal epigenetic elements that may affect gene
regulation and complex disease phenotypes.
Here, we report a methylation quantitative trait loci (meQTL)
study involving an analysis of methylation proﬁles for 380,189
CpGs and genotypes for 410,203 SNPs determined in lympho-
cytes from 898 patients with colon cancer and 850 controls, and
subsequent replication in two independent data sets totalling 577
samples. To characterize the trans-meQTL loci that are
statistically signiﬁcant, we determined whether these loci are
enriched in protein-coding and RNA-coding genes that could
mediate the trans-acting effects. We explored cis- and trans-
eQTLs correlating with meQTL loci in transcriptomic data sets
derived from 137 CD4 and 137 CD8 lymphocytes. The analyses
demonstrate an abundance of genetic loci that are associated with
distal CpG methylation, a diversity of regulatory mechanisms that
confer this role and networks of coordinated genes that are linked
to biological and/or disease processes.
Results
Description of the data set. In this study, genome-wide SNP data
and CpG methylation proﬁles detected using the Inﬁnium
HumanMethylation450 BeadChips were obtained from DNA
extracted from lymphocytes of 898 patients with colon cancer and
850 controls (after sample exclusions, see Methods) enrolled in
the Ontario Familial Colon Cancer Registry (OFCCR)6,7. We
normalized the methylation data sets and identiﬁed and ﬂagged
sites with more than 1% missing data (n¼ 13,032), calculated
after sample exclusions. We further identiﬁed CpG sites that are
polymorphic irrespective of the minor allele frequency (MAF),
sites for which at least one SNP with a MAF above 5% resides
anywhere else underneath the probe sequence (69,974 sites
derived from ref. 8) and sites that cross-hybridize with 490%
identity to multiple regions (30,436 sites). These overlapping
counts amount to 93,675 unique sites that were discarded. We
retained the methylation values (also known as the b-values) at
380,189 autosomal CpG sites, as well as genotypes for 410,203
SNPs for further analyses. The OFCCR methylation and SNP data
were deposited in dbGaP under the accession number
phs000779.v1.p1.
For the data analyses that follow, we classify a SNP–CpG
association as proximal if the SNP and the CpG site are separated
by no more than 1Mbp on the same homologous chromosome
and as distal otherwise. Over 103 million SNP–CpG pairs were
proximal candidates, and over 155 billion pairs were distal
candidates. For each CpG site, we looked for SNPs that are
associated with methylation levels in the 1,748 DNA samples; we
note that we only combined cases and controls after performing
separate analyses, which revealed over 80% overlap in signiﬁcant
results. The quantitative trait analyses were adjusted for sex, age,
blood cell type surrogate (see Methods and Supplementary
Fig. 1), batch (plate) and position of the sample on its array to get
the signiﬁcance and the proportion of the methylation variance
explained by a SNP. We retained SNP–CpG associations
consistent with an FDR (ref. 9) o5%, and report the effect size
as the proportion R2 of the CpG methylation variance that is
explained by the SNP, among the variance not already explained
by sex, age, blood cell type surrogate, batch and array position.
Proximal SNP–CpG associations. Owing to a rich body of
literature5,10–19, we present proximal SNP–CpG association
results for completeness, but focus the rest of the study on
distal (long range) associations.
Table 1 illustrates the distribution of the 52,708 CpG sites
signiﬁcantly associated with a proximal SNP (see also
Supplementary Data 1), at an FDRo5%. At this FDR threshold,
these CpG sites have at least 2.2% of their variance explained by
at least one proximal SNP, with corresponding (unadjusted)
signiﬁcance level PLRTo4.8 10 10 derived from a likelihood
ratio test (LRT). Following up these 52,708 sites by adjusting for
additional covariates to account for hidden confounders (the top
three principal components, that explain 92.5% of the variance)
does not substantially alter this list: except for 313, all remain
signiﬁcant at FDR o5%; the 313 sites that failed this threshold
nevertheless all have PLRTo1.8 10 6, with the large majority
having PLRTo10 8. The number of signiﬁcant sites decreases
with increasing variance explained; at 75% variance
explained (R240.75), the number of signiﬁcant sites drops to
338. Table 1 further breaks down the set of CpG sites based on
their variability, stratiﬁed in quintiles. As the methylation
variability of the CpG site increases, the relative proportion of
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sites correlating with a proximal SNP increases, as well as the
proportion of the variance that they explain.
Distal SNP–CpG associations. We identiﬁed 1,919 CpG sites for
which inter-individual methylation variations are signiﬁcantly
correlated with at least one distal SNP: 1,657 SNP–CpG pairs
from non-homologous chromosomes and 262 SNP–CpG distant
pairs (41Mb) located on the same homologous chromosome
(Supplementary Data 2). These counts excluded CpG sites for
which a proximal SNP was already identiﬁed. At an FDR o5%,
these distal SNPs explain at least 3.1% of the variance of their
companion CpG site, at a signiﬁcance level PLRTo3.2 10 13.
Following up these 1,919 sites by adjusting the analysis for
additional covariates consisting of the top three principal com-
ponents does not substantially alter this list: except for 33, all
remain signiﬁcant at FDR o5%; the 33 sites that failed to pass
this threshold nevertheless all have PLRTo1.5 10 10. The case–
control status is not a systematic or substantial confounder: at an
FDR o5%, only 64 of the 1,919 sites (3.3%) display signiﬁcant
differences between cases and controls, no more than what is
expected by chance alone. The very large majority (83.6%, or
1,605 pairs) of the 1,919 distal pairs are replicated in one (496
pairs) or both (1,109 pairs) replication sets (in MARTHA and/or
F5L, both totalling 577 whole-blood samples) at FDR o5%
(Supplementary Data 2), while replication of 8.5% of the pairs
(165) was not attempted in both data sets due to poor quality of
the intensity signals at the CpG sites or poor imputation quality
(R2o0.3) of the SNPs; ignoring the pairs that were not success-
fully attempted, the replication rate is thus 91.5%.
Similar to proximal pairs, where sites that showed greater
inter-individual variability are more likely to be associated with a
proximal SNP, the proportion of sites associated with a distal SNP
also increases with the site’s variability, but the increase is not as
steep (Table 2).
The 1,387 unique SNPs (Supplementary Data 2) involved in the
1,919 signiﬁcant SNP–CpG distal associations, as well as SNPs in
linkage disequilibrium (LD) (R240.5) with them, deﬁne the
boundaries of a total of 1,074 non-overlapping genomic regions
totalling 109.4Mb. Figure 1 and Supplementary Fig. 2 illustrate the
genomic landscape of meQTL loci. The regions surrounding the
SNPs harbour 2,167 RefSeq genes (1,798 coding and 369 non-
coding transcripts, including 314 long (4100 bp) non-coding
transcripts). We observe enrichment for coding (1.7-fold), non-
coding transcripts (2.0-fold) and long non-coding transcripts
(2.2-fold). We compiled a list of 190 autosomal genes involved
in epigenetic processes20 (http://www.sabiosciences.com/rt_pcr_
product/HTML/PAHS-085A.html; http://www.sabiosciences.com/
rt_pcr_product/HTML/PAHS-086A.html) (Supplementary Data
3) and ﬁnd 25 in our regions (13.2%, 2.3-fold enrichment). Of
the 1,225 manually curated, high-conﬁdence autosomal genomic
loci that encode transcription factors (TFs)21, 244 are found in the
neighbourhood of these SNPs (19.9%, 4.1-fold enrichment). Of the
388 manually curated TF that are zinc-ﬁnger proteins (ZNFs), 155
are in our regions (39.9%, 8.75-fold enrichment). Also noteworthy
in these regions are the presence of piRNA (piwi-interacting RNA;
Genbank accession numbers (with DQ preﬁx) enumerated in ref.
22): 3,072 piRNA sequences are detected, typically in clusters, near
these SNPs; this corresponds to a 3.6-fold enrichment compared
with random regions of the genome. Repetitive elements such as
short interspersed nucleotide elements (1.2-fold), and more
speciﬁcally of the Alu family (1.5-fold), were also slightly
enriched. Note that for all of the above features, the observed
number of features per Mb exceeds the corresponding number of
features in randomly selected regions in all 1,000 replicates,
effectively providing point estimates of signiﬁcance of Po0.001
Table 1 | Number of CpG sites signiﬁcantly associated with at least one proximal SNP.
R2 All sites Q1 (0–2.1%) Q2 (2.1–4.7%) Q3 (4.7–10.9%) Q4 (10.9–21.4%) Q5 (21.4–100%)
2–5% 19,216 769 1,775 3,521 5,920 7,229
5–10% 14,494 355 951 2,234 4,508 6,444
10–25% 12,284 164 515 1,498 3,490 6,616
25–50% 4,960 22 89 370 1,133 3,345
50–75% 1,416 2 5 30 225 1,154
75%þ 338 0 0 1 8 329
Total 52,708 1,312 3,335 7,654 15,284 25,117
SNP, single-nucleotide polymorphism.
Counts are stratiﬁed based on the site’s inter-individual variability and R2-value (proportion of methylation variance explained) between the SNP and CpG pairs. The variability of a site is measured as its
95%-reference range (the difference between the most and least methylated individuals, among 95% of the individuals forming the central distribution of methylation values) stratiﬁed in quintiles
(Q1–Q5); percentages in brackets indicate the corresponding 95%-reference range values.
Table 2 | Number of CpG sites signiﬁcantly associated with at least one distal SNP.
R2 All sites Q1 (0–4.9%) Q2 (4.9–7.0%) Q3 (7.0–10.8%) Q4 (10.8–17.8%) Q5 (17.8–100%)
2–5% 567 80 104 106 123 154
5–10% 676 68 122 154 149 183
10–25% 441 29 66 111 116 119
25–50% 177 6 38 38 45 50
50–75% 45 0 2 6 13 24
75%þ 13 0 0 1 3 9
Total 1,919 183 332 416 449 539
SNP, single-nucleotide polymorphism.
Counts are stratiﬁed based on the site’s inter-individual variability and R2-value (proportion of methylation variance explained) between the SNP and CpG pairs. The variability of a site is measured as its
95%-reference range (the difference between the most and least methylated individuals, among 95% of the individuals forming the central distribution of methylation values) stratiﬁed in quintiles
(Q1–Q5); percentages in brackets indicate the corresponding 95%-reference range values.
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(estimated from proportions) for each of the above absolute fold
enrichments. We also observe that 195 (18.1%) of the 1,074 non-
overlapping genomic regions harbouring genetic variants
associated with meQTLs are located towards the subtelomeric
regions of the chromosomes (within 2Mbp of the chromosome’s
ends), as well as several small genomic regions containing one or
more SNPs associated with multiple CpG sites.
Genes in the SNP LD-deﬁned neighbourhoods and genes
annotated to the CpG sites they are associated with were
projected into functional interaction (FI) networks23 (a high-
throughput network of protein–protein interactions) to evaluate
which pairs display protein–protein interactions, or to see
whether genes involved in distal SNP–CpG pairs are closer in
the FI network than expected by chance. Out of the 4,131 gene–
gene pairs that can be formed by joining one SNP-annotated gene
and one of its associated CpG-annotated genes, 1,140 pairs had
both genes mapped to FI networks. The shortest path between
these pairs of genes was calculated to be 3.48 (meaning that they
are connected but only through another 2.48 genes on average),
no different from what is expected from random pairs of
connected genes (B3.50, estimated from 1,000 replicates, P¼ 0.2
estimated from proportions). Only two pairs of genes display
direct protein–protein interactions: UBE2N (annotated to
rs6538421) and UBR4 (annotated to cg00223950); and ERBB4
(annotated to rs7599312) and SH3GLB2 (annotated to
cg20548744).
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Figure 1 | Enrichment of features in regions harbouring SNPs involved in distal SNP–CpG associations. Outer histograms: number of SNPs involved in
distal SNP–CpG associations (light blue), calculated in 7.5Mb bins; number of piRNA sequences (orange); number of transcription factors (dark blue).
Inner links: SNP regions associated with four or more CpG sites. Arrows are pointing from SNPs to the CpG sites they are associated with, and are coloured
according to the chromosomes where the SNPs reside.
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Expression quantitative loci associated with distal meQTLs. We
considered the possibility that distal sites with differential CpG
methylation could display differential allelic expression of tran-
scripts that are in the vicinity of the CpG. We analysed inde-
pendent genetic and transcriptomic data sets derived from 137
CD4 and 137 CD8 lymphocytes for the presence of eQTLs
associated with the 1,387 unique SNPs involved in distal SNP–
CpG methylations.
Figure 2a,b displays quantile–quantile plots of signiﬁcance levels
against theoretical quantiles for associations between the SNPs and
expression levels of distal protein-coding and non-coding
transcripts found in their LD-deﬁned neighbourhoods, in CD4
and CD8 cells. In each cell type, the weight of the distribution
deviates towards greater levels of associations than predicted by
chance, supporting the presence of enrichment of trans-eQTLs.
Supplementary Data 2 lists the results of all tested trans-eQTL/
gene pairs, and also present cis pairs for completeness.
In Battle et al.24, trans-eQTL (interchromosomal) were
identiﬁed from a larger number of samples (922 DNA samples
derived from whole blood) for 138 genes and distant eQTL
(intrachromosomal eQTL, 41Mb from the gene) for 269 genes,
with 5 genes overlapping both lists. Six of these genes are also
displaying signiﬁcant meQTL with at least one annotated CpG
site, either with the SNP itself or one in LD with it (smallest
observed R240.70). These are: PDE4DIP (annotated to a distant
eQTL), DUSP22, PGLS, ZNF154, ZNF274 and ZNF551 (annotated
to trans-eQTLs).
Relevance of meQTLs with respect to autoimmune diseases.
We have compared the list of proximal and distal meQTLs with
autoimmune disease (AID)-associated SNPs. Using Immunobase
(https://www.immunobase.org), we generated a list of the cur-
rently known associated SNPs (non-major histocompatibility
complex). In total, we found 552 associations across 11 AID
(indexed in Immunobase; considering Crohn’s disease and
ulcerative colitis together as inﬂammatory bowel diseases)
involving 512 unique SNPs. Furthermore, since some of the
associated SNPs in one disease are in high LD (R240.8)
with associated SNPs in other diseases, this list covers a total of
447 associated loci (two are on the X chromosome). These 512
AID-associated SNPs overlap or are highly correlated (R240.8)
with 200 of the proximal meQTLs (associated with a total of 561
CpG sites) and 14 of the distal meQTLs (associated with a total of
24 CpG sites) (Supplementary Data 4). Alternatively, 161/552
(29%) of the reported AID associations overlap or correlate with
at least one proximal meQTL, and 9/552 (2%) overlap or correlate
with at least one of the distal SNPs. In terms of the 447
independent loci, these percentages are, respectively, 115/447
(26%) and 8/447 (2%). This descriptive analysis illustrates that
localization of disease-associated genes can beneﬁt from the
meQTL annotation of disease-associated SNPs.
Case studies of three trans-meQTL loci. SENP7 (Sentrin/small
ubiquitin-like modiﬁer (SUMO)-speciﬁc protease 7) is an iso-
peptidase, which catalyses the deSUMOylation of SUMO2/3-
conjugated proteins. The reversible post-translational SUMO
modiﬁcations of proteins regulate many cellular processes
including replication, transcription, recombination, chromosome
segregation and cytokinesis. SENP7 interacts with BCL6, CBX5,
KAP1 and HP1 alpha proteins, which are involved in epigenetic
repression. SENP7 was recently described to promote chromatin
relaxation in response to DNA damage, for repair and for cellular
resistance to DNA-damaging agents25. Depletion of SENP7
results in spread of heterochromatin factors and condensed
chromatin25.
In our data set, four intronic SNPs (rs2553419, rs2682386,
rs9859077 and rs2141180) of the SENP7 gene in high LD with
each other correlate with the methylation levels at numerous CpG
sites (replicated in at least MARTHA or F5L for the large
majority; Supplementary Data 2); these SNPs correlate with cis-
acting regulation of SENP7 expression in CD4 and CD8
lymphocytes (FDRo5%; PWaldo0.00015 derived from a Wald
test; Supplementary Data 2) and trans-acting regulation of several
distal genes, including ZNF154, ZNF274 and ZNF814 (Fig. 3;
Supplementary Data 2), which reside within aB250-kb region on
chromosome 19, as well as ZNF268 (chromosome 12) and LDHD
(chromosome 16). Elevated levels of SENP7 transcripts are
associated with reduced CpG methylation located in 50-ﬂanking
regions of ZNF154, ZNF274 and ZNF814 and increased transcript
levels of these genes (PWaldo0.006); other genes whose CpG
methylation is associated with SENP7 intronic SNPs show similar
trends of expression changes that do not meet the signiﬁcance
threshold (FDR45%). These data indicate that SENP7 transcript
levels regulate methylation and transcript expression of trans-
meQTLs at multiple sites.
The identiﬁcation of SENP7-regulated genes such as ZNF154
potentially extends the understanding of SENP7 function and
linkages to cancer processes. ZNF154, a putative TF expressed in
many tissues, was initially identiﬁed as commonly deleted in
thyroid adenoma26. Hypermethylation at the CpG island in the
promoter region of ZNF154, and negative correlation between
methylation and gene expression were recently described in
serous ovarian cancers, and in endometrioid ovarian and
endometrial cancers27. Methylation-mediated repression of
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Figure 2 | Quantile–quantile plot of association levels of trans-eQTL. (a) Trans-eQTL in CD4; (b) trans-eQTL in CD8. Red lines are 95% conﬁdence bands.
l is the inﬂation factor, the ratio of observed to expected medians.
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ZNF154 in ovarian cancer is associated with poor overall
survival28. In clear cell renal cell carcinoma29 and in bladder
cancer ZNF154 is hypermethylated, and ZNF154 methylation is
identiﬁed as a biomarker of bladder cancer recurrence30,31.
A chromosome 16 region of LD with rs12933229 (R240.5),
which is devoid of protein-coding genes, is rich in piRNAs and
contains RRN3P2 (a long non-coding RNA gene), is a trans-
meQTL locus associated with methylation at 20 distal CpG sites
(all replicated in both MARTHA and F5L) residing on nine non-
homologous chromosomes (Fig. 4 for selected genes whose
expression are the most strongly associated with the SNP;
Supplementary Data 5). Five of these trans-meQTL-associated
regions have independently been reported19. Enrichment of the
H3K27Ac histone marks and TF-binding sites as determined by
Chip-seq assays32, as well as the presence of spliced expressed
sequence tags (ESTs) indicate enhanced transcriptional activity in
the region encompassing the piRNA cluster (Supplementary
Fig. 3). piRNA clusters are usually transcribed as long single-
stranded RNA and processed into mature piRNAs of 25–33
nucleotides in length33,34. The rs12933229 also correlates with
cis-acting regulation of RRN3P2 expression in CD4 and CD8
lymphocytes (PWald¼ 0.0012 and PWald¼ 0.038, respectively).
Long non-coding RNA (linc) cis-eQTLs can also inﬂuence the
expression levels of downstream genes35; in this case, RRN3P2
could be a cis-regulator of piRNA transcription. Due to the
described role of piRNA in methylation, we surmise that the
trans-regulatory effects on methylation at distal genes may be
mediated by one or more of the 21 piRNA genes (which were not
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Figure 3 | The SENP7 locus and its distally associated CpG sites. (a) UCSC browser illustration of the gene structure and location of SNPs associated
with distal CpG sites. (b,c) Association in cis between expression of SENP7 in CD4 cells and (b) rs9859077, (c) rs2682386. (d) UCSC browser illustrations
of selected associated distal CpG sites and their annotated genes (from top to bottom: ZNF154, ZNF814 and ZNF274). (e) Corresponding boxplot
representations of the SNP/CpG associations. (f) Corresponding boxplot representations of the association in trans between expression of the genes in
CD4 cells with SNPs.
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measured in the lymphocyte RNA expression studies) in the
B56-kb region harbouring SNPs in LD with rs12933229. The
Piwi/piRNA pathway has been described to promote
heterochromatin formation, DNA methylation, transcriptional
and post-transcriptional gene silencing and transcriptional
activation by promoting euchromatic features34,36,37.
We observe that for 19/20 (95%) of distal CpG sites that are
associated with rs12933229, the b-value increases with each copy
of the C allele at rs12933229, suggesting that the trans-effect is
consistent in how it distally regulates methylation (Supplementary
Data 5). Interestingly, there are nine transcripts in the vicinity of
these distal CpGs that show expression level changes in CD4 cells
that are associated with rs12933229 (PWaldo5%) (Supplementary
Data 5). Two genes (ELMOD2 and SLC35A3) show increased
expression correlating with hypomethylation of their respective
CpGs (cg03944266 and cg16383001). However, we observe
increased gene expression correlating with CpG hypermethylation
for seven genes (STARD3/cg01325958, BRF1/cg02201215,
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Figure 4 | The RRN3P2 locus and its distally associated CpG sites. (a) UCSC browser illustration of the gene structure and location of SNPs associated
with distal CpG sites. (b) Association in cis between expression of RRN3P2 in CD4 cells and rs12933229. (c) UCSC browser illustrations of selected
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of the SNP/CpG associations. (e) Corresponding boxplot representations of the association in trans between expression of the genes in CD4 cells with
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BTBD6/cg02201215, MAP3K14/cg07370464, GPC2/cg13921324,
MICALL2/cg21535156 and UNKL/cg27309189). This unusual
association of increased CpG methylation and increased
expression of local transcripts does not follow the classical
‘negative correlations’ between DNA methylation and gene
expression. Recent studies comparing DNA methylation and gene
expression have reported this paradox5,14,18,38, and surmised that
the position of the CpG within the gene body may be relevant, with
DNA methylation in promoters being negatively correlated, while
DNA methylation within the gene body39 or 30untranslated
regions40 being positively correlated with gene expression,
through mechanisms not yet explained. In our data set, we do
not observe consistent patterns between the position of the CpG
and the relationships between CpG methylation and gene
expression. Further efforts are needed to tease out these effects
resulting from a number of possible mechanisms involving
chromatin state, histone modiﬁcations, TF availability and
binding, as well as post-transcriptional regulation, including
changes in RNA decay and stability by RNA-binding proteins
and levels of small RNAs.
CTCF (CCCTC-binding factor) is a zinc-ﬁnger DNA-binding
protein that functions in transcription (activation and
repression), RNA splicing, insulator activity, chromatin architec-
ture and in genomic imprinting41. It is estimated that there are
B30,000 CTCF-binding sites in the human genome42. The
rs7203742 SNP in the intron of CTCF is associated with
methylation levels at 14 CpG sites across the genome (all
replicated in MARTHA, the majority replicated in F5L;
Supplementary Data 2). For AOC2/PSME3, SEC14L1,
PGLYRP2, ETS1, C1S, GPSM1 and SLC26A11 genes (Fig. 5),
and in regions without an annotated transcript, the rs7203742-
associated CpG sites overlaps with CTCF-binding sites. This is
consistent with observations that TFs can inﬂuence methylation
at their binding sites18,43. These CpG sites reside in the promoter
regions, introns and exons (untranslated and coding) of the
associated genes. The CTCF binding to non-methylated/
hypomethylated CpG sites, and its inhibition of binding to
methylated DNA in concert with TFs and distal enhancers could
result in repression or activation of the resident transcript. Such
CTCF-mediated transcriptional repression and activation have
been described for the imprinting control region of Igf2/H19
genes41,44.
In both the CD4 and CD8 lymphocyte expression data sets
described above, we did not detect signiﬁcant eQTLs associations.
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Figure 5 | The CTCF locus and its distally associated CpG sites. (a) UCSC browser illustration of the gene structure and location of SNPs associated with
distal CpG sites, and boxplot representation of the association in cis between CTCF expression and SNP genotypes. (b–h) Distally associated CpG
sites, their gene annotations and boxplot representations of SNP–CpG associations. The Transcription Factor ChIP-seq from ENCODE tracks are displayed
in the UCSC browser illustrations to indicate CTCF-binding sites.
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However, there are published reports that independently validate
CTCF-related meQTLs. Transcriptome sequencing on lympho-
cyte messenger RNA from patients with intellectual disability
(MIM 604167), harbouring mutant CTCF, and healthy indivi-
duals identiﬁed SEC14L1 as the top-ranked dysregulated gene in
patients45. Conditional deletion of Ctcf in mice myeloid cells
resulted in 4.77-fold upregulation of C1s gene in Ctcf-deﬁcient
macrophages46. These data substantiate the repression and
activation effects of CTCF on the expression of SEC14L1 and
C1s genes, respectively.
Discussion
In this study, we demonstrate that there is extensive long-range
regulation of CpG methylation associated with genetic variation in
the genome. A strength of the study is the large sample size used
for the discovery of meQTL loci. The vast majority of our distal
associations were replicated independently, using a variety of
sampling designs (case–controls, case-only and family based),
disease (colon cancer or venous thrombosis (VT)) normalization
and statistical framework (linear models with ﬁxed-only or mixed
effects; using the methylation values as the dependent variable or
their logit-tranformations; using LRTs or robust Wald tests) and
cell type heterogeneity correction (principal component analysis;
measured); they are statistically robust. While this data set is
neither comprehensive due the incompleteness of the CpG sites
that were ascertained and the single source of tissue that was used,
the implications of the results are daunting, as it is quite likely that
the41,000 meQTLs represent the tip of the iceberg in regards to
the numbers of distal pairs linking genetic variants and with CpG
methylation that are present in the human genome. Revisiting the
data sets presented here using more powerful strategies or
combining them, as well as other data sets, by means of meta-
analyses would likely reveal other meQTLs and their distal targets.
We were able to further analyse our meQTL results in
expression data sets derived in an independent set of genotyped
lymphocytes. This allowed us to identify many genetic variants
that are associated with both differential CpG methylation and
expression affecting distal genes. We note that future studies
would beneﬁt from having methylation and expression data sets
generated in the same tissue panels, as it could enhance the
detection of interrelated effects on transcription and expression.
Nonetheless, the current data sets provided numerous examples
of this, with SENP7 being a prime example.
We focused our analyses on loci that correlate with CpG
methylation at multiple distal sites. This revealed a number of
possible regulators including SENP7, CTCF and a piRNA cluster,
although the putative mechanism of trans-regulation appears to
be different for each. While the current concepts on how each of
the regulators may affect distal regulation is only partially known,
the widespread functions that these genes are reported to have on
gene transcription and chromatin architecture are consistent with
our observations.
Finally, this study provides new avenues to understand
molecular processes that are coordinated by genetic and
epigenetic mechanisms, and study genetic loci associated with
disease predisposition.
Methods
Methylation sample description. The cases and controls used in this study were
enrolled in phase I of the OFCCR6,47. Brieﬂy, probands were selected from incident
colorectal cancer cases identiﬁed between 1 July 1997 and 30 June 2000 from the
population-based Ontario Cancer Registry. Controls were recruited through
telephone interviews in randomly selected households in Ontario. A subset of
OFCCR cases and controls were used in the Assessment of Risk for Colorectal
Cancer Tumours in Canada study that led to the identiﬁcation of a genetic risk
factor for colon cancer in the 8q24 region7 and are used in this study. Informed
consent was obtained from all participants.
Methylation proﬁling. We proﬁled 2,203 samples from 2,101 unique donors
(1,103 cases of colorectal cancer and 998 controls). Lymphocyte pellets were
extracted from whole blood using Ficoll-Paque PLUS (GE Healthcare). DNA was
extracted from lymphocytes using phenol–chloroform or the Qiagen Mini-Amp
DNA kit, except for 99 samples (90 cases, 9 controls), for which DNA was
extracted from lymphoblastoid cell lines. We used 15 ml of DNA from all samples at
concentrations averaging 90 ng ml 1 (20 ng ml 1 s.e.). DNA samples were bisulﬁte-
converted using the EZ-96 DNA Methylation-Gold Kit (Zymo Research, Orange,
CA); 4 ml of bisulﬁte-treated DNA was then analysed on the HumanMethyla-
tion450 BeadChip from Illumina according to the manufacturer’s protocol. Except
for the case/control status, the plating of the DNA samples was not based on any
speciﬁc characteristics that they might share (for example, gender and age),
effectively randomizing these factors on the arrays. Most cases and most controls
were plated and processed separately, except for 125 cases that were matched to
125 controls on 125 rows of 36 arrays; for these samples, batch and position effects
are controlled for by design.
Calculation of methylation ratios from intensities. We calculated the methy-
lation ratios (proportion of molecules that are methylated at a given site, also
known as b-value) as b¼min(M,1)/(min(M,1)þmin(U,1)) where M and U are,
respectively, the methylated and unmethylated intensity signals (possibly back-
ground-corrected signals). This is a slight modiﬁcation of GenomeStudio’s calcu-
lation: Illumina deﬁnes the ratio as b¼min(M,0)/(min(M,0)þmin(U,0)þ 100). In
this expression, the offset (100) artiﬁcially moves the methylation value away
from 1. Moreover, the possibility of the numerator being 0 makes the resulting
distribution of b-values both discrete and continuous (with point mass at 0). We
prefer our expression for b, which results in a continuous distribution that does not
bias against a fully methylated state.
Processing of idat ﬁles and normalization. We used functions from the
methylumi package from Bioconductor to read the idat ﬁles and write intensity
values to text ﬁles. We compared the methylation values (the proportion of
molecules that are methylated at a given site, also known as b-value) of a number
of normalization strategies by focusing on 64 samples that were done in duplicate
or triplicate (129 possible pairs after sample exclusions) (see Supplementary
Methods and Supplementary Figs 4–11). On the basis of these comparisons, we
hereafter use methylation values derived from data that was background-corrected
using NOOB48 followed by colour adjustments using Illumina’s normalization
probes and algorithms; BMIQ49 was then applied to the set of b-values.
Principal component analysis. We performed a principal component analysis by
ﬁrst calculating the covariance matrix between all samples using only the most
variable autosomal CpG sites, measured in terms of their 95% reference range: the
range of methylation values observed in the central 95% of the samples, or more
precisely the difference between the 97.5 and 2.5% percentiles. Using a 95%
reference range of at least 0.20, 131,045 CpG sites were used in the covariance
matrix calculation. Together, the top three principal components explain over
92.5% of the total variance. Each subsequent vector does not add substantially to
the variance explained: 98 vectors would be necessary to explain 95% of the total
variance.
Sample exclusion. We excluded from association analyses: (1) samples for
which DNA was extracted from lymphoblastoid cell lines (99 samples including 1
in duplicate); (2) samples that were outliers with respect to any one of the
internal control probes (excluding probes designed to evaluate the background
noise and probes designed to normalize the data), where an outlier is deﬁned
as any value more than three times the interquartile range away from the
closest quartile (124 samples); (3) samples that were outliers with respect to
any one of the ﬁrst 12 principal components (corresponding to the approximate
location of the elbow of the eigenvalue scree plot), recomputed after exclusion
of the samples in steps 1 and 2 (26 samples; see Supplementary Methods);
(4) samples that were not of non-Hispanic white ancestry, either self-declared or by
investigation of genetic ancestry using genome-wide SNP data (164 samples);
and (5) samples with intensities on the X or Y chromosome inconsistent with
their gender (seven samples). These overlapping counts sum up to 389 unique
samples that were excluded. For duplicate samples, we only kept the one with the
smallest number of sites with a detection P value (see below) less than 0.01.
After exclusion of samples, we were left with 1,748 samples: 898 cases (females:
58.9%; mean age: 63±8.1 s.d.) and 850 controls (females: 42%; mean age:
64.3±8.2 s.d.).
Probe exclusion. The detection P value is a quantitative assessment of the
probability that the total intensity, for a given sample at a given site, can be
distinguished from background noise, and is included along with the intensity
values. All b-values with a detection P value less than 1% were treated as missing
data. Sites with more than 1% missing values after sample exclusion were discarded
(13,032 sites).
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Polymorphic sites. We excluded from SNP–CpG-methylation association
analyses all CpG sites that were polymorphic at the cytosine or at the guanine base,
and, in the case of Inﬁnium I probes, had a SNP at the position where single-base
extension occurs (the base before the CpG cytosine), irrespective of the allele
frequency. We moreover excluded CpG sites for which a SNP resided elsewhere
within the probe target sequence as long as its MAF was above 5%. Allele
frequency estimates were extracted from the samples of European ancestry
(EUR; 379 samples) of the 1000 Genomes Project50.
Probe cross-reactivity. We excluded CpG sites from SNP–CpG-methylation
association analyses if their probe sequences aligned to multiple positions with
Z90% identity; misalignments were ignored if the terminal nucleotide of the probe
was a mismatch (preventing single-base extension), if the probe aligned with gaps
or if the probe mapped onto an alternative assembly of the target chromosome. See
ref. 8 for additional details.
Cell-type proportions. Because differences in cell-type proportions between DNA
samples can confound association results51, we adjusted our analyses using a
surrogate for cell-type proportions derived from 49 differentially methylated CpG
sites present on the HumanMehtylation450 array that have the ability of
discriminating between blood cell types52. As a surrogate for cell-type proportions,
and to reduce the number of variables, we used the ﬁrst two principal components
associated with these 49 sites that together explain over 90% of the total variance.
To verify that the ﬁrst two principal components that we derived from the list of
49 differentially methylated CpG sites52 can indeed serve as a surrogate for blood
cell proportions, we tested for associations between the principal components and
the methylation levels at all of our sites, adjusting our analyses for sex, age, arrays
and position of the samples on the arrays. We selected the top 10% of the sites that
showed the strongest associations (46,000 sites, all associated at levels Po10 100)
and extracted these sites in data sets of puriﬁed human leukocyte subtypes53 (GEO
accession: GSE39981); 2,605 sites were overlapping. A dendrogram representation
of our top sites in this data set53 reveals clear clustering of samples according to cell
types, indicating a good ability for principal components to discriminate between
samples with different cell compositions (Supplementary Fig. 1).
Genetic variants and inter-individual levels of methylation. For each CpG site,
we looked for SNPs that were associated with inter-individual methylation levels;
we treated the methylation levels as a quantitative trait, and searched the genome
for quantitative trait loci (meQTL) that explained a substantial proportion of the
methylation variance at that site. We used SNP data from a colon cancer genome-
wide association study7 (a 1536 GoldenGate panel from Illumina; the 10-k coding-
SNP array from Affymetrix/ParAllele; the Human Mapping 100-k set from
Affymetrix) all combined and complemented with the Human Mapping 500-k set
from Affymetrix. When combining SNPs genotyped on multiple platforms or
arrays, SNPs with more than 0.5% discordant calls were discarded; otherwise
discordant calls were considered to be missing calls. SNPs with minor allele
frequencies less than 5% in either the cases or the controls were ignored, as well as
SNPs with genotypic frequencies inconsistent with Hardy–Weinberg equilibrium at
Po10 4 in all samples and SNPs with call rates less than 90%; in all, 410,203
autosomal SNPs were available for pairwise comparison with 380,189 autosomal
methylation sites.
We classify a SNP–CpG association as proximal if the SNP and the CpG site are
separated by no more than 1Mbp on the same homologous chromosome and as
distal otherwise. Over 103 million SNP–CpG pairs were proximal candidates, while
over 155 billion pairs were distal candidates. Preliminary analyses in cases and
controls separately revealed over 80% overlap in signiﬁcant results at stringent
signiﬁcance thresholds; we thus combined cases and controls to increase power.
We analysed the SNP–CpG pairs using a linear regression framework
implemented in R: the b-value of a methylation site was taken as the independent
variable, genotypes (number of minor alleles) at a SNP were taken as the values of
the independent variable and the model included sex, age, case/control status, cell-
type proportion surrogate, batch (plate) and position of the sample on its array as
covariates. Signiﬁcance of the SNP was calculated from a LRT (PLRT). Rare
homozygous genotypes (count of less than 10) were combined with heterozygotes.
Following this analysis, we report SNP–CpG associations consistent with an FDR
(ref. 9) o5%, and report the effect size as the proportion R2 of the CpG
methylation variance that is explained by the SNP, among the variance not already
explained by the covariates.
We stratify results based on the inter-individual variability of the CpG sites. As
a measure of variability, we used the 95%-reference range (the difference between
the most and least methylated individuals, among 95% of the individual forming
the central distribution of methylation values), which is less sensitive to outliers
than the full range and more readily interpretable than the s.d.
All genomic positions are reported with respect to the hg19/GRCh37 coordinates.
A circular representation of distal SNP–CpG associations with ideograms was
plotted using CIRCOS54.
SNP–CpG replication sets. We sought to replicate distal SNP–CpG associations
using two sets. (1) F5L: a set of 227 French–Canadian individuals belonging to ﬁve
extended families (each ascertained through a single proband with idiopathic VT
and carrying the factor V Leiden mutation55. These whole-blood samples were
proﬁled on the HumanMethylation450 array and genotyped on the Human660W-
Quad array from Illumina. We chose proxy SNPs from the Human660W-Quad
array that are in high LD with SNPs involved in distal SNP–CpG associations when
the latter were not present on the Illumina array; to seek consistency in the
direction of association, we report phasing information and strength of LD between
the pairs of SNPs (based on 1000 Genomes EUR data). (2) MARTHA: a set of 350
unrelated cases of VT patients of European ancestry (primarily of French descent)
from the MARseille THrombosis Association study55,56. These whole-blood
samples were proﬁled on the HumanMethylation450 array and genotyped on the
Human610-Quad array from Illumina. Imputation of ungenotyped SNPs was
performed using MACH v1.0.16a and minimac v4.4.3 (ref. 57) with their
accompanying 1000 Genomes-based reference set58. We report the R2 measure of
imputation accuracy.
All three sets (OFCCR, F5L and MARTHA) were analysed independently by the
different groups providing the data, using methods and software seen as most
appropriate for their own samples. Both F5L and MARTHA methylation data were
normalized similarly to the OFCCR data set, with the exception that SWAN59 was
used instead of BMIQ. For F5L, methylation values of the different CpG sites (beta
values) were ﬁrst logit-transformed and modelled as a linear function of the
number of SNP alleles in a linear mixed regression model that included a random
effect to account for the relatedness of the samples (implemented in GEMMA60);
the model was furthermore adjusted for age, sex and cell-type proportions61.
Signiﬁcance was assessed using a LRT. For MARTHA, a linear regression model
was used where the methylation values were taken as the outcome that was
modelled using the allele dosage (from imputation) as the predictor, while adjusted
for age, sex, batch, array, position of the sample on its array and measured cell-type
compositions (lymphocytes, monocytes, polynuclear, eosinophils and basophils
directly determined by ADVIA 120 Hematology System (Siemens Healthcare
Diagnostics, Deerﬁeld, IL)). Signiﬁcance was assessed using a Wald test.
SNP and CpG site annotations. We annotated sets of genes or features (for
example, non-coding RNAs) to SNPs by selecting the smallest genomic region that
contained all SNPs in high LD with a SNP of interest (at R240.5 according to 1000
Genomes50 data or HapMap release 22 when the SNP is not indexed in 1000
Genomes Project) and annotated to that SNP all genes (that were extended by 5 kb
in their promoter regions) or features falling at least partially in that window. We
counted the number of features falling in regions ﬂanking our meQTLs. By
randomly selecting a similar number of SNPs among the ones that entered the
analysis and generating LD-deﬁned regions, we calculated an average absolute fold
enrichment of genomic features (fold enrichment of features per Mb) based on
1,000 replicates. Signiﬁcance of feature fold-enrichment was calculated as the
proportion of random replicates (sets of random regions) having a number of
features greater or equal to the observed number of features in our meQTL regions.
These fold enrichments are not meant to be compared with what is expected in
random regions of the genome per se, but rather random regions of the subset of
the genome that is covered by our set of SNPs, as well as SNPs in LD with them.
A CpG site was annotated to a gene if its location falls from within 1,500 bases
from the gene’s transcription start sites up to and including its 30untranslated
region. This set of annotations is available with the HumanMethylation450 array
documentation.
Functional interaction networks. We downloaded version 2013 of the FI network
from Reactome (www.reactome.org) that we analysed using functions from the
igraph package of R (www.r-project.org).
Expression data sets in CD4 and CD8 lymphocytes. The expression data from
puriﬁed T-cell subpopulations was derived from multiple sclerosis (MS) patients
(n¼ 68) and healthy controls (n¼ 67). MS cases were recruited through the
Cambridge MS clinic and controls from the Cambridge (UK) BioResource (http://
www.cambridgebioresource.org.uk). The study had approval from appropriate
ethics committees and all subjects gave written informed consent. In total 50–80ml
of heparinized whole blood was collected from each individual and peripheral
blood mononuclear cells (PBMCs) isolated using Ficoll density-gradient cen-
trifugation. PBMCs were washed twice following Ficoll separation to remove pla-
telet contamination. DNA was prepared from aliquots of the PBMCs using
standard isolation protocols. CD4þ and CD8þ T cells were isolated using
magnetic-activated cell sorting according to the manufacturers’ instructions (Mil-
tenyi Biotec). Speciﬁcally CD3þ cells were negatively selected using a Pan T Cell
Isolation Kit followed by positive selection of CD8þ cells with the remaining
fraction representing CD4þ cells. The purity of the separated cells was checked by
ﬂow cytometry for a subset of the samples.
The isolated cells were immediately lysed in TRIzol reagent (Life Technologies)
and stored at  80 C prior to extraction. Total RNA was extracted according to
the standard TRIzol protocol, and DNA contamination removed using DNase I
treatment (Thermo Scientiﬁc). The extracted RNA was cleaned using the RNeasy
MinElute Cleanup Kit (Qiagen), and the RNA integrity assessed using an Agilent
2100 Bioanalyzer and quantiﬁed using a Nanodrop 1000. Libraries for stranded
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total RNA-sequencing were prepared using the Illumina Stranded Total RNA
protocol (RS-122-2301). Libraries were assessed using the Agilent 2100
Bioanalyzer.
Samples were indexed and sequenced on Illumina HiSeq 2000 (paired-end
2 100 bp). Raw reads were trimmed for quality (phred33Z30), length (nZ32)
and Illumina adapters using Trimmomatic v. 0.22 (ref. 62). Filtered reads were
aligned to the hg19 human reference (for human samples) using Tophat v. 1.4.1
(ref. 63) and bowtie v. 0.12.8 (ref. 64). Duplicates were marked in the bam ﬁle using
Picard’s MarkDuplicates.jar v. 1.70 (http://picard.sourceforge.net). Raw read counts
for ucsc and ensembl genes were obtained using htseq-count v. 0.5.3p9 (http://
www-huber.embl.de/users/anders/HTSeq). FPKM values (fragments per kilobase
of transcript per million fragments mapped) for ucsc and ensembl genes and
transcripts were obtained using cufﬂinks v. 2.1.1 (ref. 65). To reduce the distorting
effects of high data values in sequence data, we transformed all FPKM values with
the inverse hyperbolic sine function asinh x¼ ln(xþO(x2þ 1)) and ﬁnally
performed quantile normalization across signal-transformed FPKMs. Genotyping
on the 137 samples was performed on Illumina Human 2.5M arrays, and
additional variants were imputed (Impute2) using 1000 Genomes (phase 1
integrated version 3) UK sample as reference. Association testing for genotype
versus normalized FPKMs was carried out using PLINK66 using a linear framework
for successfully imputed sites (info40.8) without covariates, combining the cases
and controls but separating CD4þ and CD8þ to independent data sets.
Signiﬁcance was calculated using a Wald statistic (PWald).
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